ethyl 2-(benzo[d][1,3]dioxolane-5-yl-amino)thiazole-4-carboxylate | 1493079-23-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: ethyl 2-(benzo[d][1,3]dioxolane-5-yl-amino)thiazole-4-carboxylate
• 英文别名: Ethyl 2-(1,3-benzodioxol-5-ylamino)-1,3-thiazole-4-carboxylate；ethyl 2-(1,3-benzodioxol-5-ylamino)-1,3-thiazole-4-carboxylate
• CAS: 1493079-23-4
• 化学式: C₁₃H₁₂N₂O₄S
• 分子量: 292.315
• InChiKey: WZTUFZIAGBEOME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  97.9
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  ethyl 2-(benzo[d][1,3]dioxolane-5-yl-amino)thiazole-4-carboxylate 在 乙醇 、 sodium hydroxide 作用下， 生成 2-(benzo[d][1,3]dioxol-5-ylamino)thiazole-4-carboxylic acid
  参考文献：
  名称：

  The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophore

  摘要：

  Lead optimization of piperidine amide HTS hits, based on an anilino-thiazole core, led to the identification of analogs which displayed low nanomolar blocking activity at the canonical transient receptor channels 3 and 6 (TRPC3 & 6) based on FLIPR (carbachol stimulated) and electrophysiology (OAG stimulated) assays. In addition, the anilino-thiazole amides displayed good selectivity over other TRP channels (TRPA1, TRPV1, and TRPV4), as well as against cardiac ion channels (CaV1.2, hERG, and NaV1.5). The high oxidation potential of the aliphatic piperidine and aniline groups, as well as the lability of the thiazole amide group contributed to the high clearance observed for this class of compounds. Conversion of an isoquinoline amide to a naphthyridine amide markedly reduced clearance for the bicyclic piperidines, and improved oral bioavailability for this compound series, however TRPC3 and TRPC6 blocking activity was reduced substantially. Although the most potent anilino-thiazole amides ultimately lacked oral exposure in rodents and were not suitable for chronic dosing, analogs such as 14-19, 22, and 23 are potentially valuable in vitro tool compounds for investigating the role of TRPC3 and TRPC6 in cardiovascular disease. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.06.047
• 作为产物：
  描述：

  N-(benzo[d][1,3]dioxol-5-ylcarbamothioyl)benzamide 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 7.0h， 生成 ethyl 2-(benzo[d][1,3]dioxolane-5-yl-amino)thiazole-4-carboxylate
  参考文献：
  名称：

  高效选择性CYP1B1抑制剂的设计、合成及生物学评价

  摘要：

  CYP1B1 被认为是治疗癌症的有前途的目标。然而，由于 CYP1B1/1A1/1A2 活性位点之间的密切相似性，考虑到 CYP1A2 对药物代谢至关重要，而 CYP1A1 仅在特定恶性肿瘤中大量表达并参与药物代谢，因此发现兼具活性和选择性的 CYP1B1 抑制剂具有挑战性代谢。本研究通过结构修饰获得了一种高效选择性的CYP1B1抑制剂C9 ，其对CYP1B1的抑制活性为2.7 nM，对CYP1A1和1A2的选择性分别超过37037和7407倍。此外，C9有效恢复Taxol对A549/Taxol细胞的敏感性，抑制A549/Taxol细胞迁移。分子对接和分子动力学 (MD) 模拟表明，C9在与 CYP1B1 的结合中形成了必要的相互作用，并且可以保持相对稳定。总之，C9可以作为一种有效的选择性 CYP1B1 抑制剂进行进一步研究。

  DOI：

  10.1039/d2nj05691g

文献信息

• N-芳基-[2,4′-双噻唑]-2′-胺类化合物及其制备与用途
  申请人：沈阳药科大学

  公开号：CN114249702B

  公开（公告）日：2023-09-05

  本发明的N‑芳基‑[2,4'‑双噻唑]‑2'‑胺类化合物及其制备与用途，该化合物结构如通式I所示，为活性成分的药物组合物，其中取代基U、V、W、X具有在说明书中给出的含义。本发明还涉及通式I的化合物具有强的CYP1B1酶抑制作用，并且还涉及该类化合物及其光学异构体、药学上可接受的盐在制备用于治疗和/或预防由于CYP1B1异常表达所引起疾病的药物中的应用，特别是在制备治疗和/或预防癌症的药物中的用途。
• The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophore
  作者：David G. Washburn、Dennis A. Holt、Jason Dodson、Jeff J. McAtee、Lamont R. Terrell、Linda Barton、Sharada Manns、Anna Waszkiewicz、Christina Pritchard、Dan J. Gillie、Dwight M. Morrow、Elizabeth A. Davenport、Irina M. Lozinskaya、Jeffrey Guss、Jonathan B. Basilla、Lorena Kallal Negron、Michael Klein、Robert N. Willette、Rusty E. Fries、Timothy C. Jensen、Xiaoping Xu、Christine G. Schnackenberg、Joseph P. Marino

  DOI：10.1016/j.bmcl.2013.06.047

  日期：2013.9

  Lead optimization of piperidine amide HTS hits, based on an anilino-thiazole core, led to the identification of analogs which displayed low nanomolar blocking activity at the canonical transient receptor channels 3 and 6 (TRPC3 & 6) based on FLIPR (carbachol stimulated) and electrophysiology (OAG stimulated) assays. In addition, the anilino-thiazole amides displayed good selectivity over other TRP channels (TRPA1, TRPV1, and TRPV4), as well as against cardiac ion channels (CaV1.2, hERG, and NaV1.5). The high oxidation potential of the aliphatic piperidine and aniline groups, as well as the lability of the thiazole amide group contributed to the high clearance observed for this class of compounds. Conversion of an isoquinoline amide to a naphthyridine amide markedly reduced clearance for the bicyclic piperidines, and improved oral bioavailability for this compound series, however TRPC3 and TRPC6 blocking activity was reduced substantially. Although the most potent anilino-thiazole amides ultimately lacked oral exposure in rodents and were not suitable for chronic dosing, analogs such as 14-19, 22, and 23 are potentially valuable in vitro tool compounds for investigating the role of TRPC3 and TRPC6 in cardiovascular disease. Published by Elsevier Ltd.
• Design, synthesis and biological evaluation of highly potent and selective CYP1B1 inhibitors
  作者：Haoyu Zhang、Ping Xu、Ting Wang、Shiyu Wang、Weixia Li、Jianping Mao、Jian Wang、Fengjiao Zhang、Maosheng Cheng

  DOI：10.1039/d2nj05691g

  日期：——

  activity and selectivity considering CYP1A2 is crucial for drug metabolism whereas CYP1A1 is only abundantly expressed in specific malignancies and involved in drug metabolism. In this study, a highly potent and selective CYP1B1 inhibitor C9 was obtained by structural modification, with an inhibitory activity of 2.7 nM against CYP1B1, and more than 37037 and 7407 fold selectivity over CYP1A1 and 1A2

  CYP1B1 被认为是治疗癌症的有前途的目标。然而，由于 CYP1B1/1A1/1A2 活性位点之间的密切相似性，考虑到 CYP1A2 对药物代谢至关重要，而 CYP1A1 仅在特定恶性肿瘤中大量表达并参与药物代谢，因此发现兼具活性和选择性的 CYP1B1 抑制剂具有挑战性代谢。本研究通过结构修饰获得了一种高效选择性的CYP1B1抑制剂C9 ，其对CYP1B1的抑制活性为2.7 nM，对CYP1A1和1A2的选择性分别超过37037和7407倍。此外，C9有效恢复Taxol对A549/Taxol细胞的敏感性，抑制A549/Taxol细胞迁移。分子对接和分子动力学 (MD) 模拟表明，C9在与 CYP1B1 的结合中形成了必要的相互作用，并且可以保持相对稳定。总之，C9可以作为一种有效的选择性 CYP1B1 抑制剂进行进一步研究。